WindMIL Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • WindMIL Therapeutics's estimated annual revenue is currently $2M per year.(i)
  • WindMIL Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • WindMIL Therapeutics has 13 Employees.(i)
  • WindMIL Therapeutics grew their employee count by -19% last year.

WindMIL Therapeutics's People

NameTitleEmail/Phone
1
EVP,CSO,FounderReveal Email/Phone
2
Senior Manager and Scientist IReveal Email/Phone
3
Senior Manager and Scientist IReveal Email/Phone
4
Laboratory TechnicianReveal Email/Phone
5
EVP,CSO,FounderReveal Email/Phone
6
Laboratory TechnicianReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is WindMIL Therapeutics?

WindMIL Therapeutics is a clinical stage oncology cell therapy company. We are leveraging our proprietary platform to develop a novel class of cell therapies called MILsâ„¢ (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$2M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

WindMIL Therapeutics News

2022-04-19 - Cell Therapy and Tissue Engineering Market – increasing ...

Betalin Therapeutics, BioCardia Inc, BioReliance Corporation, Biosolution Co., ... Waisman Biomanufacturing, WindMIL Therapeutics Inc., Wuxi App Tec Inc.,...

2022-04-19 - Cell Therapy and Tissue Engineering Market – increasing ...

Betalin Therapeutics, BioCardia Inc, BioReliance Corporation, Biosolution Co., ... Waisman Biomanufacturing, WindMIL Therapeutics Inc., Wuxi App Tec Inc.,...

2022-04-06 - IN8bio Continues to Build on its Clinical and Regulatory Team ...

... gamma-delta T cell therapies utilizing its DeltEx platform, ... as the VP of Regulatory and Quality Systems at WindMIL Therapeutics.

2022-04-06 - IN8bio Continues to Build on its Clinical and Regulatory Team ...

... gamma-delta T cell therapies utilizing its DeltEx platform, ... as the VP of Regulatory and Quality Systems at WindMIL Therapeutics.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M13-71%N/A
#2
$1.4M13-19%N/A
#3
$1.2M13-7%N/A
#4
$2M1344%N/A
#5
$2M13-19%N/A